Action grants on substances of human origin (SoHo) - Increase resilience, ensure continuity of supply and access to safe and high quality therapies, in particular in times of crisis
The Action Grants on Substances of Human Origin (SoHo) program aims to bolster the resilience and ensure the continuous, safe, and high-quality supply of therapies derived from human substances, especially during public health crises. This initiative specifically addresses vulnerabilities highlighted by the COVID-19 pandemic, focusing on optimizing supply chains and improving access to critical SoHo therapies across the European Union.
Who is Funded
The EU4Health program targets medical and professional organizations, alongside Member State authorities, to enhance health systems across the European Union. Its primary goal is to foster resilience and ensure continuous access to safe and high-quality therapies derived from human substances, particularly during crisis situations. The geographical scope encompasses all European Union Member States.
What is Funded
This funding supports activities focused on enhancing the safety, quality, and accessibility of therapies involving substances of human origin (SoHo). Projects will primarily involve the development and dissemination of good practices, targeting various sub-sectors within healthcare. The expected impact includes the strengthening of transplant, transfusion, and medically assisted reproduction systems.
Type and Scope of Funding
The financial support for this program is provided through action grants, with a significant budget allocation dedicated to increasing resilience and access to therapies involving substances of human origin. The maximum funding available for this specific topic is 3,500,000 €.
Conditions and Requirements
Applicants must adhere to specific conditions for admissibility, eligibility, and financial capacity. The application process and grant agreement stipulations are detailed in the official call document, emphasizing the importance of adherence to European Union regulations.
Application Procedure
The application process involves preparing and submitting proposals in accordance with guidelines detailed in the official call document and online manual. The selection process is competitive, with evaluation based on defined award criteria.
Legal Basis
This funding program operates under a robust legal framework, primarily authorized by specific European Union regulations and governed by the broader financial rules of the EU. Official texts providing the legal basis are accessible to ensure transparency and compliance.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
3,500,000 €
Allocated Budget:
3,500,000 €
Open Until:
Ongoing
Award Channel:
Competitive Tender
Region:
European Union (across all Member States)
Sectors:
Healthcare, Medical Technology, Pharmaceutical Industry, Research and Development
Beneficiaries:
Healthcare sector, medical professionals, public health authorities
Application Type:
Consortium Required
Funding Stages:
Applied Research, Implementation, Capacity Building
Funding Provider
Program Level:
European Union
Funding Body:
European Commission
Managed By:
HaDEA (European Health and Digital Executive Agency)
Website: